Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
NCT01763164
Last updated date
ABOUT THIS STUDY
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the
efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in
patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61
mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be
performed at a central laboratory. Only those patients with Q61 mutation per central
laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will
be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified
according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0
versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This
study will use an Interactive Response Technology (IRT). The primary end point of the study
is progression-free survival. Key secondary end point is overall survival
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic or Unresectable Cutaneous Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)
- Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory
- Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma
- Evidence of at least one measurable lesion as detected by radiological or photographic methods
- Adequate bone marrow, organ function, cardiac and laboratory parameters
- Normal functioning of daily living activities
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Any untreated CNS metastases
- Uveal or mucosal melanoma
- History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO
- Patients with washout period < 6 weeks from the last dose of ipilimumab or other
immunotherapy.
- Previous systemic chemotherapy for unresectable locally advanced or metastatic
melanoma.
- History of Gilbert's syndrome
- Prior therapy with a MEK- inhibitor
- Impaired cardiovascular function or clinically significant cardiovascular diseases
- Uncontrolled arterial hypertension despite medical treatment
- HIV positive or active Hepatitis A or B
- Impairment of gastrointestinal function
- Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting
study drug or who have not recovered from side effects of such procedure;
- Patients with neuromuscular disorders that are associated with elevated CK.
- Pregnant or nursing (lactating) women
- Medical, psychiatric, cognitive or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study
Other protocol-defined inclusion/exclusion criteria may apply
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Metastatic or Unresectable Cutaneous MelanomaStudy Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
NCT01763164
- Fayetteville, Arkansas
- Rogers, Arkansas
- Altamonte Springs, Florida
- Bonita Springs, Florida
- Bradenton, Florida
- Brandon, Florida
- Cape Coral, Florida
- Clearwater, Florida
- Clearwater, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Hudson, Florida
- Inverness, Florida
- Largo, Florida
- Largo, Florida
- Naples, Florida
- Naples, Florida
- New Port Richey, Florida
- Orange City, Florida
- Orlando, Florida
- Port Charlotte, Florida
- Saint Petersburg, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Sarasota, Florida
- Spring Hill, Florida
- Tampa, Florida
- Tampa, Florida
- Tavares, Florida
- Venice, Florida
- Venice, Florida
- Niles, Illinois
- Park Ridge, Illinois
- Goshen, Indiana
- Bangor, Maine
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Bingham Farms, Michigan
- Detroit, Michigan
- Detroit, Michigan
- Farmington Hills, Michigan
- Omaha, Nebraska
- Hackensack, New Jersey
- Hackensack, New Jersey
- Voorhees, New Jersey
- Columbus, Ohio
- Columbus, Ohio
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Allentown, Pennsylvania
- Allentown, Pennsylvania
- Bethlehem, Pennsylvania
- Bethlehem, Pennsylvania
- Easton, Pennsylvania
- Hershey, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Quakertown, Pennsylvania
- Nashville, Tennessee
- Austin, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Fort Worth, Texas
- The Woodlands, Texas
- Buenos Aires, Ciudad Autónoma DE Buenosaires
- Viedma, RÍO Negro
- Rosario, Santa FE
- Buenos Aires,
- Camperdown, New South Wales
- Gateshead, New South Wales
- North Sydney, New South Wales
- Woolloongabba, Queensland
- Adelaide, South Australia
- Graz, Steiermark
- Innsbruck, Tirol
- Salzburg,
- Vienna,
- Wilrijk, Antwerpen
- Leuven,
- Liege,
- Passo Fundo, RIO Grande DO SUL
- Porto Alegre, RIO Grande DO SUL
- Rio de Janeiro,
- Sao Paulo,
- Edmonton, Alberta
- London, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Quebec,
- Brno, Jihomoravský KRAJ
- Ostrava,
- Praha 10,
- Praha 2,
- Angers, Maine-et-loire
- Lille, Nord
- Lyon, Rhône
- Bordeaux,
- Boulogne Billancourt,
- Le Mans,
- Marseille,
- Nice,
- Paris,
- Pierre Benite,
- Reims,
- Rouen,
- Freiburg im Breisgau, Baden-württemberg
- Mannheim, Baden-württemberg
- München, Bayern
- Regensburg, Bayern
- Würzburg, Bayern
- Frankfurt, Hessen
- Frankfurt, Hessen
- Buxtehude, Niedersachsen
- Minden, Nordrhein-westfalen
- Quedlinburg, Sachsen-anhalt
- Leipzig, Sachsen
- Berlin, Schleswig-holstein
- Erfurt, Thüringen
- Dresden,
- Essen,
- Gera,
- Hannover,
- Heidelberg,
- Kiel,
- Koeln,
- Lübeck,
- Münster,
- Nürnberg,
- Tübingen,
- Ulm,
- Athens,
- Budapest,
- Budapest,
- Kaposvár,
- Szolnok,
- Haifa,
- Jerusalem,
- Ramat Gan,
- Napoli, Campania
- Napoli, Campania
- Roma, Lazio
- Brescia, Lombardia
- Padova, Veneto
- Bari,
- Bergamo,
- Genova,
- Milano,
- Milano,
- Roma,
- Siena,
- Torino,
- Matsumoto, Nagano
- Chuo-ku,
- Hirakata-city,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Nijmegen, Gelderland
- Amsterdam, Noord-holland
- Leiden, Zuid-holland
- Zwolle,
- Warszawa, Mazowieckie
- Warszawa,
- Warszawa,
- Lisbon, Lisboa
- Almada,
- Lisboa,
- Porto,
- Moscow,
- Ryazan,
- St. Petersburg,
- Bratislava,
- Bloemfontein, FREE State
- Johannesburg, Gauteng
- Johannesburg, Gauteng
- Pretoria, Gauteng
- Pretoria, Gauteng
- L'Hospitalet de Llobregat, Barcelona
- Malaga, Málaga
- Pamplona, Navarra
- Barcelona,
- Barcelona,
- Barcelona,
- Gran Canaria,
- La Coruna,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Sevilla,
- Toledo,
- Valencia,
- Valencia,
- Lund,
- Zurich, Zürich (DE)
- Genève,
- Lausanne,
- Bornova, Izmir
- Adana,
- Ankara,
- Ankara,
- Istanbul,
- Bristol, Bristol, CITY OF
- Truro, Cornwall
- Brighton, EAST Sussex
- Chelmsford, Essex
- Swansea, Glamorgan
- Preston, Lancashire
- London, London, CITY OF
- Birmingham,
- Leeds,
- Wirral,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | ||||||
| Official Title ICMJE | The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma | ||||||
| Brief Summary | Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type ICMJE | Interventional | ||||||
| Study Phase ICMJE | Phase 3 | ||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
| Condition ICMJE | Metastatic or Unresectable Cutaneous Melanoma | ||||||
| Intervention ICMJE |
| ||||||
| Study Arms ICMJE |
| ||||||
| Publications * | Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status ICMJE | Completed | ||||||
| Actual Enrollment ICMJE | 402 | ||||||
| Original Estimated Enrollment ICMJE | 393 | ||||||
| Actual Study Completion Date ICMJE | June 4, 2019 | ||||||
| Actual Primary Completion Date | December 1, 2015 (Final data collection date for primary outcome measure) | ||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply | ||||||
| Sex/Gender ICMJE |
| ||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries ICMJE | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States | ||||||
| Removed Location Countries | Czech Republic | ||||||
| Administrative Information | |||||||
| NCT Number ICMJE | NCT01763164 | ||||||
| Other Study ID Numbers ICMJE | CMEK162A2301 C4211002 ( Other Identifier: Alias Study Number ) 2012-003593-51 ( EudraCT Number ) | ||||||
| Has Data Monitoring Committee | Yes | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement ICMJE |
| ||||||
| Responsible Party | Pfizer | ||||||
| Study Sponsor ICMJE | Pfizer | ||||||
| Collaborators ICMJE | Not Provided | ||||||
| Investigators ICMJE |
| ||||||
| PRS Account | Pfizer | ||||||
| Verification Date | December 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||||||